Want to see IN:LALPATHLAB full AI Analyst Report?
LALPATHLAB Stock Chart & Stats
₹1756.70
₹68.00(3.87%)
At close: 4:00 PM EDT
₹1756.70
₹68.00(3.87%)
Day’s Range― - ―
52-Week Range₹1,272.00 - ₹1,939.00
Previous CloseN/A
Volume2.11M
Average Volume (3M)3.61K
Market Cap
₹319.77B
Enterprise Value₹208.76K
Total Cash (Recent Filing)₹13.31B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)58.7
Beta0.55
Next Earnings
Oct 28, 2026EPS Estimate
10.53Next Dividend Ex-DateN/A
Dividend Yield0.84%
Share Statistics
EPS (TTM)32.44
Shares Outstanding167,637,770
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio12.69
Price to Book (P/B)8.73
Price to Sales (P/S)7.93
P/FCF Ratio40.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.97
Revenue Forecast (FY)₹32.01B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet With Very Low LeverageVery low debt-to-equity gives durable financial flexibility: it lowers interest burden, preserves capacity for capital spending or M&A, and helps the company withstand demand shocks. Improved leverage since FY2023 supports longer-term investment without stressing cash flow.
Strong Operating Cash GenerationSustained positive operating cash flow and coverage above 1.0 indicate high earnings quality and internal funding for network expansion, equipment capex and working capital. This underpins the hub-and-spoke roll-out and reduces reliance on external financing over multi-quarter horizons.
Resilient, Multi-year Revenue GrowthConsistent revenue expansion reflects durable end-market demand and diversified B2C/B2B channels. A steady top-line supports scale benefits for central labs, helps dilute fixed costs over time and strengthens the economics of collection-network investments.
Bears Say
FY2026 Margin CompressionSharp gross-margin deterioration undermines unit economics and reduces funds available for reinvestment or margin recovery initiatives. If structural (pricing pressure or cost inflation), sustained margin compression can materially lower long-term returns and constrain strategic options.
Weaker Free Cash Flow Conversion And VolatilityDeclining FCF conversion and historical swings signal working-capital or capex timing risk. Variable FCF increases funding uncertainty for expansion and dividends, and can force episodic external financing in periods of capex or receivable buildup.
Decelerating Revenue Growth RateSlowing top-line growth may reflect market saturation, intensifying competition, or pricing headwinds. Over the medium term this reduces potential operating-leverage gains and raises execution risk for maintaining historical ROE and expansion plans without new service lines.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1272.00 and its highest was ₹1939.00 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹319.77B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is Oct 28, 2026 which is in 85 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Jul 24, 2026. The company reported ₹10.1 earnings per share for the quarter, beating the consensus estimate of ₹8.691 by ₹1.409.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Overvalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Monthly dividend of ₹5 which represents an annual dividend yield of 0.84%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 10.53.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,637,770 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹10.1 in its last earnings report, beating expectations of ₹8.691. Following the earnings report the stock price went up 4.15%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to conducting pathological investigations across various specialized fields. These include biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, in addition to other general pathological and radiological studies. Beyond its core testing operations, Dr. Lal PathLabs also offers laboratory staff training, technical support, and full-scale lab management services. As of March 31, 2022, its widespread infrastructure included 277 clinical laboratories, notably a National Reference Lab located in Delhi and a Regional Reference Lab in Kolkata. This is further bolstered by 4,731 patient service centers and 10,599 sample collection points. Founded in 1949, Dr. Lal PathLabs Limited maintains its corporate base in Gurugram, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―